Dartmouth Radiotherapy Technology a First for Cancer Treatment

Dartmouth-Hitchcock’s cancer center is the first to install BeamSite Cherenkov imaging cameras in its radiotherapy treatment rooms. The camera system, invented by entrepreneurs from Norris Cotton Cancer Center (NCCC) and Dartmouth startup, DoseOptics, LLC—co-founded by Dartmouth engineering professor Brian Pogue—captures real-time imaging of the beam on the patient, allowing the oncology team to adjust and optimize treatment.

Enabling this visualization of treatment delivery, the Cherenkov effect occurs when photon or electron radiation beams interact with tissue, such as skin, producing a small light emission from the surface. BeamSite cameras capture images of the treatment-beam shapes in real time, as well as show levels of intensity proportional to the radiation dose. These visual data can verify accuracy of both dose and beam delivery at each treatment, a verification not possible using conventional quality assurance measures.

“Cherenkov imaging provides visualization of the radiation therapy treatment, so that the treatment team can see everything, and make adjustments when unexpected things happen,” explains Pogue, the MacLean Professor of Engineering at Dartmouth and President of DoseOptics. A joint engineering and oncology team reviewed events recorded in their Cherenkov imaging study over the course of a few years, during which they documented incidents when radiotherapy delivery was not ideal and the adjustments made to rectify. Their findings, “Initial Clinical Experience of Cherenkov Imaging in External Beam Radiation Therapy Identifies Opportunities to Improve Treatment Delivery,” have been published in The International Journal of Radiation Oncology, Biology, Physics.

There were a total of 64 patients in the study, under the supervision of radiation oncologist and lead author Lesley Jarvis, member of NCCC’s Translational Engineering in Cancer Research Program and Associate Professor at Geisel School of Medicine. The patients were receiving treatment for breast cancer, sarcoma, lymphoma and other cancers. Six patients were found to indicate that adjustments would have improved treatment, such as stray radiation exposure to the opposite breast, arm, or chin during treatments. The imaging system was also used to identify when inadvertent dose was not an issue, such as confirming no unintended exposure of the opposite leg during an extremity sarcoma treatment.

Radiation therapy is a repetitive procedure given to patients daily for approximately 30 days. Setting patients up on the treatment couch and alignment of the beam is a complex process. Beyond positional complications, the therapy team must leave the room when the beam is on, so if anything happens during delivery, problem-solving tools are limited. National statistics show that incidents of incorrect delivery might occur on a level of approximately 1 percent. In a busy clinic, this could mean one patient per week. “Normally the treatments are just fine,” says Pogue, who also serves as co-director of the Translational Engineering in Cancer Research Program at NCCC. “However, if you cannot see where the beam is, then it is a blind treatment, and the interaction between patient and therapy team is just less natural than it could be if the treatment was visual.”

NCCC is currently the only cancer center in the world with regular use of Cherenkov imaging in all radiotherapy treatments, and was uniquely positioned for clinical research teams to test out these cameras for the planned study. Cherenkov imaging cameras have been installed in most linear accelerators within Dartmouth-Hitchcock, providing an extra level of safety during each patient’s therapy session. “Cherenkov cameras mounted inside the radiotherapy treatment rooms give us the ability to simply see the treatment and provide an intuitive guide to therapists that we otherwise wouldn’t have had,” says Pogue. “This is a terrific tool for tracking what happens each day and in each treatment, and for improving the quality of radiotherapy delivery.”

DoseOptics’ technology was developed through research at Dartmouth by Dartmouth faculty, who then licensed the product to the company. Pioneered at Dartmouth-Hitchcock, it is now expanding to other cancer centers. Since DoseOptics received FDA clearance to market BeamSite in December of 2020, the team hopes all radiation oncology clinics will introduce the technology to their programs. “Clinics should have all the tools available to them to ensure that each treatment for each patient is accurate, and to be able to quickly notice issues and fix them,” says Pogue.